Eosinophilic Disorders in Various Diseases

详细信息    查看全文

• 作者：Jocelyn Celestin (1)
  Marianne Frieri (2)
  
• 关键词：Eosinophils ; Eosinophilic disorders ; Interleukins ; Eotaxin ; T cells ; Inflammation ; Eosinopoietic ; Imatinib ; Eosinophilic esophagitis
• 刊名：Current Allergy and Asthma Reports
• 出版年：2012
• 出版时间：February 2012
• 年：2012
• 卷：12
• 期：1
• 页码：18-24
• 全文大小：143KB
• 参考文献：1. Ehrlich P, Beitr盲ge zur Kenntnis der granulierenden Bindegewebszellen und der eosinophilen Leukocyten. Arch Anat Physiol 1879; 166鈥?69.
  2. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147鈥?4. CrossRef
  3. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79:3101鈥?.
  4. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119:1291鈥?00. CrossRef
  5. Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome. Curr Allergy Asthma Res. 2006;6:215鈥?0. CrossRef
  6. Lecki MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000;356:2144鈥?. CrossRef
  7. Apter AJ. Advances in adult asthma diagnosis and treatment and HEDQ in 2010. J Allergy Clin Immunol. 2011;127:116鈥?2. CrossRef
  8. 鈥osenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 1245鈥?. / This editorial by two well-known authors on the subject substantiates the potential role of anti鈥揑L-5 in the treatment of respiratory conditions associated with eosinophilia. CrossRef
  9. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985鈥?3. This article highlights the prednisone sparing effect of anti鈥揑L-5 in patients with asthma and sputum eosinophilia. CrossRef
  10. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmunity Reviews. 2006;5:160鈥?. CrossRef
  11. 鈥⑩€hillips EJ, Chung W-H, Mockenhaupt M et al., Drug hypersensitivity: Pharmacogenetics and clinical syndromes, J Allergy Clin Immunol 2011; 127: S60-6. / This article is the latest in a series indicating the role of eosinophils in drug reactions. CrossRef
  12. Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1995;25(7):560鈥?. CrossRef
  13. Nagai Y, Mori T, Abe T, Nomura G. Immediate-type allergy against human insulin associated with type with marked eosinophilia in type 2 diabetic patient. Endocr J. 2001;48:311鈥?. CrossRef
  14. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the T_H1/T_H2 cytokine balance toward increased levels of the cytokines and IgE, markers of allergy: a review. Virus Genes. 2006;33:235鈥?2.
  15. Wilson ME, Weller PF. Eosinophilia. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens and practice. Philadelphia: Churchill Livingstone; 2006. p. 1478鈥?5.
  16. Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol. 2007;45(1):26鈥?0. CrossRef
  17. Frieri M, Akkina S, Anand P. A case of persistent eosinophilia in lupus nephritis. Ann Allergy Asthma Immunol. 2011;107:P108.
  18. Simon HU, Seger R. Hyper-IgE syndrome associated with an IL-4-producing 纬/未 + T-cell clone. J Allergy Clin Immunol. 2007;119:246鈥?. CrossRef
  19. Schaffer JV. The changing face of graft-versus-host disease. Semin Cutan Med Surg. 2006;25:190鈥?00. CrossRef
  20. Jacobsohn DA, Schechter T, Seshadri R, et al. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation. 2004;77:1096鈥?00. CrossRef
  21. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77(1):82鈥?. CrossRef
  22. Frieri M. Mastocytosis, Chapter 14. Humana Press, 2009.
  23. Shahzad G, Mustacchia P, Frieri M. Role of mucosal inflammation in eosinophilic esophagitis: Review of the literature, International Scholarly Research Network (ISRN) Gastroenterology, vol. 2011, Article ID 468073, 7pages, 2011.
  24. 鈥⑩€iacouras CA, Furuta GT, Hirano I, Atkins D et al., Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3鈥?0. / This article is a comprehensive review of the latest about the etiology, pathogenesis, and treatment of EE. CrossRef
  25. Stein ML, Collins MH, Villanueva JM, et al. Anti-interleukin-5(mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2007;118:1312鈥?. CrossRef
  26. Blanchard N, Wang KF, Stringer, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest. 2006;116(2):536鈥?7. CrossRef
  27. Arora S, Yamazaki K. Eosinophilic esophagitis: asthma of the esophagus? Clin Gastroenterol Hepatol. 2004;2(7):523鈥?0. CrossRef
  28. Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology. 2009;137(4):1238鈥?9. CrossRef
  29. Knight K, Bl谩zquez AB, Zhang S, Mayer L, Sampson HA, Berin MC. CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice. Am J Physiol. 2007;293(6):G1234鈥?3.
  30. Rothenberg ME: Eosinophilic Gastroenteropathies. In Middleton鈥檚 Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. (eds), Elsevier; 2008: 879鈥?91.
  31. Foroughi S, Prussin C. Clinical management of eosinophilic gastrointestinal disorders. Curr Allergy Asthma Rep. 2005;5:259鈥?1. CrossRef
  32. Campos LE, Pereira LF. Pulmonary eosinophilia. J Bras Pneumol. 2009;35(6):561鈥?3
  33. Allen JN, Magro CM, King MA. The eosinophilic pneumonias. Semin Respir Crit Care Med. 2002; Apr;23(2):127鈥?4.
  34. Alam M, Burki NK. Chronic eosinophilic pneumonia: a review. South Med J. 2007 Jan;100(1):49鈥?3
  35. Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol. 2005;52:32鈥?. CrossRef
  36. Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin鈥檚 disease with eosinophilia. Blood. 1990;75:13鈥?.
  37. Cordovi, MV, Verma, V, Gotlieb V Frieri M. Lymphocyte rich Hodgkin鈥檚 lymphoma presented with warm hemolytic anemia. a case report and literature review. Case Reports in Hematology, 2011.
  38. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndrome. Allergy. 2004;59:673鈥?9. CrossRef
  39. Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;3:535鈥?9. CrossRef
  40. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukemias. Br J Haematol. 2003;122:173鈥?. CrossRef
  41. Keung YK, Beaty M, Steward W, et al. Chronic myelocitic leukemia with eosinophilia, t(9,12)(q34;p13) and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet. 2002;138:139鈥?2. CrossRef
  42. Chang HW, Leong KH, Koh DR, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651鈥?.
  43. Fletcher S, Bain B. Eosinophilic leukaemia. Br Med Bull. 2007;81鈥?:115鈥?7. CrossRef
  44. Weller PF: Eosinophilia and Eosinophil-Related Disorders. In: Middleton鈥檚 Allergy Principles and Practice. Edited by Adkinson FN, Busse WW, Bochner BS et al. Elsevier; 2008: 859鈥?77.
  45. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target for imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201鈥?4. CrossRef
  46. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114(1):52鈥?0. CrossRef
  47. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101(12):4714鈥?. CrossRef
  48. Jain N, Cortes J, Quintas-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res. 2009;33(6):837鈥?. CrossRef
  49. Nand R, Bryke C, Kroft SH, et al. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosin kinase inhibitors. Leuk Res. 2009;33(8):1144鈥?. CrossRef
  50. Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest. 2005;128:3681鈥?. CrossRef
  
• 作者单位：Jocelyn Celestin (1)
  Marianne Frieri (2)
  
  1. Division of Allergy and Immunology, Department of Medicine and Pediatrics, Albany Medical College, 176 Washington Avenue Extension, Albany, NY, 12203, USA
  2. Division of Allergy Immunology, Nassau University Medical Center, 2201 Hempstead Turnpike, East Meadow, NY, 11554, USA
  

文摘

Peripheral and tissue eosinophilia are usually associated with a variety of inflammatory, malignant, and infectious conditions. As the presence of eosinophils in the tissues may cause significant cellular damage to vital organs such as the heart, tissue eosinophilia should be diagnosed and treated promptly. One operative way to evaluate eosinophilic disorders is to classify them into extrinsic and intrinsic. While extrinsic eosinophilic disorders are usually due to the production of eosinopoietic factors derived from T cells or tumor cells, the intrinsic types generally are the result of genetic mutations in the eosinophilic lineage. As we understand more the biology of eosinophils, only a few eosinophilic disorders remain idiopathic. The purpose of this article is to help the clinician classify in an operational manner most eosinophilic disorders, using the extrinsic and intrinsic model. This may facilitate not only a better understanding of the role of eosinophils in these disorders, but also help the systematic clinical work-up and potential treatment of affected patients.